Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

Abstract Background A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a chimeric oncolytic adenovirus suitable for intravenous (i.v.) delivery due to its capsid modification and...

Cijeli opis

Bibliografski detalji

Glavni autori:	Elise Jirovec, Dafne C. A. Quixabeira, James H. A. Clubb, Santeri A. Pakola, Tatiana Kudling, Victor Arias, Lyna Haybout, Katriina Jalkanen, Tuomo Alanko, Tine Monberg, Amir Khammari, Brigitte Dreno, Inge Marie Svane, Matthew S. Block, Daniel A. Adamo, Johanna Mäenpää, Claudia Kistler, Suvi Sorsa, Otto Hemminki, Anna Kanerva, João M. Santos, Victor Cervera-Carrascon, Akseli Hemminki
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2024-11-01
Serija:	Journal of Experimental & Clinical Cancer Research
Teme:	Oncolytic Virus TILT-123 Intravenous Delivery Adenovirus Solid Tumors Immunotherapy
Online pristup:	https://doi.org/10.1186/s13046-024-03219-0
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!